The impact of COVID-19 on diagnostic biomarkers in neuropsychiatric and neuroimmunological diseases: a review.
COVID-19
SARS-CoV-2
biomarkers
neuroimmunological diseases
neuropsychiatric
Journal
Reviews in the neurosciences
ISSN: 2191-0200
Titre abrégé: Rev Neurosci
Pays: Germany
ID NLM: 8711016
Informations de publication
Date de publication:
27 01 2022
27 01 2022
Historique:
received:
25
12
2020
accepted:
24
04
2021
pubmed:
5
6
2021
medline:
18
1
2022
entrez:
4
6
2021
Statut:
epublish
Résumé
Coronavirus disease 2019 (COVID-19) is an infectious respiratory disease, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Evidence-based emerging reports of neurological manifestations show that SARS-CoV-2 can attack the nervous system. However, little is known about the biomarkers in disease in neuropsychiatric and neuroimmunological disorders. One of the important keys in the management of COVID-19 is an accurate diagnosis. Biomarkers could provide valuable information in the early detection of disease etiology, diagnosis, further treatment, and prognosis. Moreover, ongoing investigations on hematologic, biochemical, and immunologic biomarkers in nonsevere, severe, or fatal forms of COVID-19 patients provide an urgent need for the identification of clinical and laboratory predictors. In addition, several cytokines acting through mechanisms to emerge immune response against SARS-CoV-2 infection are known to play a major role in neuroinflammation. Considering the neuroinvasive potential of SARS-CoV-2, which can be capable of triggering a cytokine storm, the current evidence on inflammation in psychiatry and neurodegenerative by emerging neuroinflammation is discussed in this review. We also highlighted the hematologic, biochemical, and immunologic biomarkers in COVID-19 diagnosis. COVID-19 prognostic biomarkers in patients with neuropsychiatric and neuroimmunological diseases are also explained.
Identifiants
pubmed: 34087964
pii: revneuro-2020-0154
doi: 10.1515/revneuro-2020-0154
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
79-92Informations de copyright
© 2021 Walter de Gruyter GmbH, Berlin/Boston.
Références
Abate, G., Memo, M., and Uberti, D. (2020). Impact of COVID-19 on Alzheimer’s disease risk: viewpoint for research. Multidisciplinary Digital Publishing Institute (MDPI) Action. Healthcare 8: 286.
Achar, A. and Ghosh, C. (2020). Covid-19-Associated neurological disorders: the potential route of cns invasion and blood-brain relevance. Cells 9: 2360, https://doi.org/10.3390/cells9112360.
Antonini, A., Leta, V., Teo, J., and Chaudhuri, K.R. (2020). Outcome of Parkinson’s Disease patients affected by COVID‐19. Mov. Disord 35: 905–908.
Baig, A.M., Khaleeq, A., Ali, U., and Syeda, H. (2020). Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host–virus interaction, and proposed neurotropic mechanisms. ACS Chem. Neurosci. 11: 995–998, https://doi.org/10.1021/acschemneuro.0c00122.
Balcioglu, Y.H., Yesilkaya, U.H., Gokcay, H., and Kirlioglu, S.S. (2020). May the central nervous system be fogged by the cytokine storm in COVID-19?: an appraisal. J. Neuroimmune Pharmacol. 15: 343–344, https://doi.org/10.1007/s11481-020-09932-9.
Batlle, D., Soler, M.J., Sparks, M.A., Hiremath, S., South, A.M., Welling, P.A., and Swaminathan, S. (2020). Acute kidney injury in COVID-19: emerging evidence of a distinct pathophysiology. J. Am. Soc. Nephrol. 31: 1380–1383, https://doi.org/10.1681/asn.2020040419.
Bellavance, M.-A. and Rivest, S. (2014). The HPA–immune axis and the immunomodulatory actions of glucocorticoids in the brain. Front. Immunol. 5: 136, https://doi.org/10.3389/fimmu.2014.00136.
Benameur, K., Agarwal, A., Auld, S.C., Butters, M.P., Webster, A.S., Ozturk, T., Howell, J.C., Bassit, L.C., Velasquez, A., and Schinazi, R.F. (2020). Encephalopathy and encephalitis associated with cerebrospinal fluid cytokine alterations and coronavirus disease, Atlanta, Georgia, USA, 2020. Emerg. Infect. Dis. 26: 2016, https://doi.org/10.3201/eid2609.202122.
Benros, M.E., Nielsen, P.R., Nordentoft, M., Eaton, W.W., Dalton, S.O., and Mortensen, P.B. (2011). Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study. Am. J. Psychiatr. 168: 1303–1310, https://doi.org/10.1176/appi.ajp.2011.11030516.
Bhaskar, S., Sinha, A., Banach, M., Mittoo, S., Weissert, R., Kass, J.S., Rajagopal, S., Pai, A.R., and Kutty, S. (2020). Cytokine storm in COVID-19—immunopathological mechanisms, clinical considerations, and therapeutic approaches: the REPROGRAM Consortium position paper. Front. Immunol. 11: 1648, https://doi.org/10.3389/fimmu.2020.01648.
Bianchetti, A., Rozzini, R., Guerini, F., Boffelli, S., Ranieri, P., Minelli, G., Bianchetti, L., and Trabucchi, M. (2020). Clinical presentation of COVID19 in dementia patients. J. Nutr. Health Aging 24: 560–562, https://doi.org/10.1007/s12603-020-1389-1.
Bollo, L., Guerra, T., Bavaro, D.F., Monno, L., Saracino, A., Angarano, G., Paolicelli, D., Trojano, M., and Iaffaldano, P. (2020). Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide. J. Neurol. Sci. 416: 117011, https://doi.org/10.1016/j.jns.2020.117011.
Bossù, P., Toppi, E., Sterbini, V., and Spalletta, G. (2020). Implication of aging related chronic neuroinflammation on COVID-19 pandemic. J. Personalized Med. 10: 102, https://doi.org/10.3390/jpm10030102.
Boziki, M.K., Mentis, A.-F.A., Shumilina, M., Makshakov, G., Evdoshenko, E., and Grigoriadis, N. (2020). COVID-19 immunopathology and the central nervous system: implication for multiple sclerosis and other autoimmune diseases with associated demyelination. Brain Sci. 10: 345, https://doi.org/10.3390/brainsci10060345.
Brann, D.H., Tsukahara, T., Weinreb, C., Lipovsek, M., Van den Berge, K., Gong, B., Chance, R., Macaulay, I.C., Chou, H.-J., and Fletcher, R.B. (2020). Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia. Sci. Adv. 6: eabc5801, https://doi.org/10.1126/sciadv.abc5801.
Brindley, R.L., Bauer, M.B., Blakely, R.D., and Currie, K.P. (2017). Serotonin and serotonin transporters in the adrenal medulla: a potential hub for modulation of the sympathetic stress response. ACS Chem. Neurosci. 8: 943–954, https://doi.org/10.1021/acschemneuro.7b00026.
Chai, X., Hu, L., Zhang, Y., Han, W., Lu, Z., Ke, A., Zhou, J., Shi, G., Fang, N., and Fan, J. (2020). Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. biorxiv preprint.
Chan, A.S. and Rout, A. (2020). Use of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in COVID-19. J. Clin. Med. Res. 12: 448, https://doi.org/10.14740/jocmr4240.
Chen, X., Laurent, S., Onur, O.A., Kleineberg, N.N., Fink, G.R., Schweitzer, F., and Warnke, C. (2021). A systematic review of neurological symptoms and complications of COVID-19. J. Neurol. 268: 392–402, https://doi.org/10.1007/s00415-020-10067-3.
Chen, X., Zhao, B., Qu, Y., Chen, Y., Xiong, J., Feng, Y., Men, D., Huang, Q., Liu, Y., and Yang, B. (2020). Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients. Clin. Infect. Dis. ciaa: 449.
Chew, N.W., Lee, G.K., Tan, B.Y., Jing, M., Goh, Y., Ngiam, N.J., Yeo, L.L., Ahmad, A., Khan, F.A., and Shanmugam, G.N. (2020). A multinational, multicentre study on the psychological outcomes and associated physical symptoms amongst healthcare workers during COVID-19 outbreak. Brain Behav. Immun 88: 559–565.
Chiappelli, J., Shi, Q., Kodi, P., Savransky, A., Kochunov, P., Rowland, L.M., Nugent, K.L., and Hong, L.E. (2016). Disrupted glucocorticoid—immune interactions during stress response in schizophrenia. Psychoneuroendocrinology 63: 86–93, https://doi.org/10.1016/j.psyneuen.2015.09.010.
Codo, A.C., Davanzo, G.G., de Brito Monteiro, L., de Souza, G.F., Muraro, S.P., Virgilio-da-Silva, J.V., Prodonoff, J.S., Carregari, V.C., de Biagi Junior, C.A.O., and Crunfli, F. (2020). Elevated glucose levels favor SARS-CoV-2 infection and monocyte response through a HIF-1α/glycolysis-dependent axis. Cell Metabol. 32: 437–446: e435, https://doi.org/10.1016/j.cmet.2020.07.007.
Coolen, T., Lolli, V., Sadeghi, N., Rovai, A., Trotta, N., Taccone, F.S., Creteur, J., Henrard, S., Goffard, J.-C., and Dewitte, O. (2020). Early postmortem brain MRI findings in COVID-19 non-survivors. Neurology 95: 2016–2027, 10.1212/WNL.0000000000010116.
del Rey, A. and Besedovsky, H.O. (2017). Immune-neuro-endocrine reflexes, circuits, and networks: physiologic and evolutionary implications. Endocr. Immunol. 48: 1–18, https://doi.org/10.1159/000452902.
Demirci, S., Demirci, S., Kutluhan, S., Koyuncuoglu, H.R., and Yurekli, V.A. (2016). The clinical significance of the neutrophil-to-lymphocyte ratio in multiple sclerosis. Int. J. Neurosci. 126: 700–706, https://doi.org/10.3109/00207454.2015.1050492.
Desforges, M., Le Coupanec, A., Dubeau, P., Bourgouin, A., Lajoie, L., Dubé, M., and Talbot, P.J. (2020). Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system? Viruses 12: 14, https://doi.org/10.3390/v12010014.
Diao, B., Wang, C., Tan, Y., Chen, X., Liu, Y., Ning, L., Chen, L., Li, M., Liu, Y., and Wang, G. (2020). Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front. Immunol. 11: 827, https://doi.org/10.3389/fimmu.2020.00827.
Djelilovic-Vranic, J. and Alajbegovic, A. (2012). Role of early viral infections in development of multiple sclerosis. Med. Arch. 66: 37, https://doi.org/10.5455/medarh.2012.66.s37-s40.
Dodding, M.P. and Way, M. (2011). Coupling viruses to dynein and kinesin‐1. EMBO J. 30: 3527–3539, https://doi.org/10.1038/emboj.2011.283.
Erta, M., Quintana, A., and Hidalgo, J. (2012). Interleukin-6, a major cytokine in the central nervous system. Int. J. Biol. Sci. 8: 1254, https://doi.org/10.7150/ijbs.4679.
Fathi, N., and Rezaei, N. (2020). Lymphopenia in COVID-19: therapeutic opportunities Cell. Biol. Int. 44: 1792–1797.
Ferini-Strambi, L., and Salsone, M. (2020). COVID-19 and neurological disorders: are neurodegenerative or neuroimmunological diseases more vulnerable? J. Neurol. 68: 409–419, https://doi.org/10.1007/s00415-020-10070-8.
Follmer, C. (2020). Viral infection-induced gut dysbiosis, neuroinflammation, and α-synuclein aggregation: updates and perspectives on COVID-19 and neurodegenerative disorders. ACS Chem. Neurosci. 11: 4012–4016.
Frank-Cannon, T.C., Alto, L.T., McAlpine, F.E., and Tansey, M.G. (2009). Does neuroinflammation fan the flame in neurodegenerative diseases? Mol. Neurodegener. 4: 1–13, https://doi.org/10.1186/1750-1326-4-47.
Fuchs, F., Damm, J., Gerstberger, R., Roth, J., and Rummel, C. (2013). Activation of the inflammatory transcription factor nuclear factor interleukin-6 during inflammatory and psychological stress in the brain. J. Neuroinflammation 10: 905, https://doi.org/10.1186/1742-2094-10-140.
Garbers, C., Heink, S., Korn, T., and Rose-John, S. (2018). Interleukin-6: designing specific therapeutics for a complex cytokine. Nat. Rev. Drug Discov. 17: 395–412, https://doi.org/10.1038/nrd.2018.45.
García-Azorín, D., Martínez-Pías, E., Trigo, J., Hernández-Pérez, I., Valle-Peñacoba, G., Talavera, B., Simón-Campo, P., de Lera, M., Chavarría-Miranda, A., and López-Sanz, C. (2020). Neurological comorbidity is a predictor of death in Covid-19 disease: a cohort study on 576 patients. Front. Neurol. 11: 781.
Ghahramani, S., Tabrizi, R., Lankarani, K.B., Kashani, S.M.A., Rezaei, S., Zeidi, N., Akbari, M., Heydari, S.T., Akbari, H., and Nowrouzi-Sohrabi, P. (2020). Laboratory features of severe vs. non-severe COVID-19 patients in Asian populations: a systematic review and meta-analysis. Eur. J. Med. Res. 25: 1–10.https://doi.org/10.1186/s40001-020-00432-3.
Gralinski, L.E. and Menachery, V.D. (2020). Return of the coronavirus: 2019-nCoV. Viruses 12: 135, https://doi.org/10.3390/v12020135.
Grolli, R.E., Mingoti, M.E.D., Bertollo, A.G., Luzardo, A.R., Quevedo, J., Réus, G.Z., and Maria, Z. (2021). Impact of COVID-19 in the mental health in elderly: psychological and biological updates. Mol. Neurobiol. 58.
Hamming, I., Timens, W., Bulthuis, M., Lely, A., Navis, G.V., and van Goor, H. (2004). Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 203: 631–637, https://doi.org/10.1002/path.1570.
Han, H., Ma, Q., Li, C., Liu, R., Zhao, L., Wang, W., Zhang, P., Liu, X., Gao, G., and Liu, F. (2020). Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg. Microb. Infect. 9: 1123–1130, https://doi.org/10.1080/22221751.2020.1770129.
Hanaei, S., and Rezaei, N. (2020). COVID-19: developing from an outbreak to A pandemic. Arch. Med. Res. 51: 582–584.
Hannan, M.A., Islam, M.N., and Uddin, M.J. (2020). Self-confidence as an immune-modifying psychotherapeutic intervention for COVID-19 patients and understanding of its connection to CNS-endocrine-immune axis. J. Adv. Biotechnol. Exp. Therapeut. 3: 14–17, https://doi.org/10.5455/jabet.2020.d151.
Hauer, D., Weis, F., Krauseneck, T., Vogeser, M., Schelling, G., and Roozendaal, B. (2009). Traumatic memories, post-traumatic stress disorder and serum cortisol levels in long-term survivors of the acute respiratory distress syndrome. Brain Res. 1293: 114–120, https://doi.org/10.1016/j.brainres.2009.04.014.
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., and Gu, X. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395: 497–506, https://doi.org/10.1016/s0140-6736(20)30183-5.
Jakhmola, S., Indari, O., Chatterjee, S., and Jha, H.C. (2020). SARS-CoV-2, an underestimated pathogen of the nervous system. SN Compr. Clin. Med. 2: 2137–2146, https://doi.org/10.1007/s42399-020-00522-7.
Kempuraj, D., Selvakumar, G.P., Ahmed, M.E., Raikwar, S.P., Thangavel, R., Khan, A., Zaheer, S.A., Iyer, S.S., Burton, C., and James, D. (2020). COVID-19, mast cells, cytokine storm, psychological stress, and neuroinflammation. Neuroscientist 26: 402–414, https://doi.org/10.1177/1073858420941476.
Kennedy, R. and Silver, R. (2016). Neuroimmune signaling: cytokines and the CNS. Neuroscience in the 21st century. Springer, New York, pp. 1–41.
Keyhanian, K., Umeton, R.P., Mohit, B., Davoudi, V., Hajighasemi, F., and Ghasemi, M. (2020). SARS-CoV-2 and nervous system: from pathogenesis to clinical manifestation. J. Neuroimmunol. 350: 577436, https://doi.org/10.1016/j.jneuroim.2020.577436.
Khartabil, T., Russcher, H., van der Ven, A., and De Rijke, Y. (2020). A summary of the diagnostic and prognostic value of hemocytometry markers in COVID-19 patients. Crit. Rev. Clin. Lab Sci. 57: 415–431, https://doi.org/10.1080/10408363.2020.1774736.
Koenigsknecht-Talboo, J. and Landreth, G.E. (2005). Microglial phagocytosis induced by fibrillar β-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J. Neurosci. 25: 8240–8249, https://doi.org/10.1523/jneurosci.1808-05.2005.
Kong, X., Zheng, K., Tang, M., Kong, F., Zhou, J., Diao, L., Wu, S., Jiao, P., Su, T., and Dong, Y. (2020). Prevalence and factors associated with depression and anxiety of hospitalized patients with COVID-19. MedRxiv-preprint, https://doi.org/10.1126/science.caredit.abc4052.
Kubota, T., and Kuroda, N. (2021). Exacerbation of preexisting neurological symptoms and COVID-19 severity in patients with comorbid neurological disorders and COVID-19: a systematic review. Clin. Neurol. Neurosurg. 200: 106349.
Kuyumcu, M.E., Yesil, Y., Oztürk, Z.A., Kizilarslanoğlu, C., Etgül, S., Halil, M., Ulger, Z., Cankurtaran, M., and Arıoğul, S. (2012). The evaluation of neutrophil-lymphocyte ratio in Alzheimer’s disease. Dement. Geriatr. Cognit. Disord. 34: 69–74, https://doi.org/10.1159/000341583.
Lechien, J.R., Chiesa-Estomba, C.M., De Siati, D.R., Horoi, M., Le Bon, S.D., Rodriguez, A., Dequanter, D., Blecic, S., El Afia, F., and Distinguin, L. (2020). Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur. Arch. Oto-Rhino-Laryngol. 277: 2251–2261.
Lennon, J.C. (2020). Neurologic and immunologic complications of COVID-19: potential long-term risk factors for Alzheimer’s disease. J. Alzheim. Dis. Rep. 4: 217–221, https://doi.org/10.3233/adr-200190.
Leow, M.K.S., Kwek, D.S.K., Ng, A.W.K., Ong, K.C., Kaw, G.J.L., and Lee, L.S.U. (2005). Hypocortisolism in survivors of severe acute respiratory syndrome (SARS). Clin. Endocrinol. 63: 197–202.https://doi.org/10.1111/j.1365-2265.2005.02325.x.
Lin, L., Zheng, L.J., and Zhang, L.J. (2018). Neuroinflammation, gut microbiome, and Alzheimer’s disease. Mol. Neurobiol. 55: 8243–8250, https://doi.org/10.1007/s12035-018-0983-2.
Lippi, G., Plebani, M., and Henry, B.M. (2020). Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin. Chim. Acta 506: 145–148, https://doi.org/10.5935/1676-2444.20200035.
Mahalaxmi, I., Kaavya, J., Mohana Devi, S., and Balachandar, V. (2020). COVID‐19 and olfactory dysfunction: a possible associative approach towards neurodegenerative diseases. J. Cell. Physiol. 236: 763–770, https://doi.org/10.1002/jcp.29937.
Mandel, M., Harari, G., Gurevich, M., and Achiron, A. (2020). Cytokine prediction of mortality in COVID19 patients. Cytokine 134: 155190, https://doi.org/10.1016/j.cyto.2020.155190.
Maripuu, M., Wikgren, M., Karling, P., Adolfsson, R., and Norrback, K.-F. (2014). Relative hypo-and hypercortisolism are both associated with depression and lower quality of life in bipolar disorder: a cross-sectional study. PloS One 9: e98682, https://doi.org/10.1371/journal.pone.0098682.
Marreiros, R., Müller-Schiffmann, A., Trossbach, S.V., Prikulis, I., Hänsch, S., Weidtkamp-Peters, S., Moreira, A.R., Sahu, S., Soloviev, I., and Selvarajah, S. (2020). Disruption of cellular proteostasis by H1N1 influenza A virus causes α-synuclein aggregation. Proc. Natl. Acad. Sci. U.S.A. 117: 6741–6751, https://doi.org/10.1073/pnas.1906466117.
Meduri, G.U., Headley, S., Kohler, G., Stentz, F., Tolley, E., Umberger, R., and Leeper, K. (1995). Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS: plasma IL-1β and IL-6 levels are consistent and efficient predictors of outcome over time. Chest 107: 1062–1073, https://doi.org/10.1378/chest.107.4.1062.
Mehta, P., McAuley, D.F., Brown, M., Sanchez, E., Tattersall, R.S., Manson, J.J., and Collaboration, H.A.S. (2020). COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395: 1033, https://doi.org/10.1016/s0140-6736(20)30628-0.
Morris, G., Anderson, G., and Maes, M. (2017). Hypothalamic-pituitary-adrenal hypofunction in myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS) as a consequence of activated immune-inflammatory and oxidative and nitrosative pathways. Mol. Neurobiol. 54: 6806–6819, https://doi.org/10.1007/s12035-016-0170-2.
Morris, G., Stubbs, B., Köhler, C.A., Walder, K., Slyepchenko, A., Berk, M., and Carvalho, A.F. (2018). The putative role of oxidative stress and inflammation in the pathophysiology of sleep dysfunction across neuropsychiatric disorders: focus on chronic fatigue syndrome, bipolar disorder and multiple sclerosis. Sleep Med. Rev. 41: 255–265, https://doi.org/10.1016/j.smrv.2018.03.007.
Naka, T., Nishimoto, N., and Kishimoto, T. (2002). The paradigm of IL-6: from basic science to medicine. Arthritis Res. Ther. 4: 1–10, https://doi.org/10.1186/ar565.
Nampoothiri, S., Sauve, F., Ternier, G., Fernandois, D., Coelho, C., Imbernon, M., Deligia, E., Perbet, R., Florent, V., and Baroncini, M. (2020). The hypothalamus as a hub for SARS-CoV-2 brain infection and pathogenesis. bioRxiv peprint.
Netland, J., Meyerholz, D.K., Moore, S., Cassell, M., and Perlman, S. (2008). Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J. Virol. 82: 7264–7275, https://doi.org/10.1128/jvi.00737-08.
Olender, T., Keydar, I., Pinto, J.M., Tatarskyy, P., Alkelai, A., Chien, M.-S., Fishilevich, S., Restrepo, D., Matsunami, H., and Gilad, Y. (2016). The human olfactory transcriptome. BMC Genom. 17: 1–18, https://doi.org/10.1186/s12864-016-2960-3.
Oyola, M.G. and Handa, R.J. (2017). Hypothalamic–pituitary–adrenal and hypothalamic–pituitary–gonadal axes: sex differences in regulation of stress responsivity. Stress 20: 476–494, https://doi.org/10.1080/10253890.2017.1369523.
Palao, M., Fernández-Díaz, E., Gracia-Gil, J., Romero-Sánchez, C., Díaz-Maroto, I., and Segura, T. (2020). Multiple sclerosis following SARS-CoV-2 infection. Mult. Scler. Relat. Disord. 45: 102377, https://doi.org/10.1016/j.msard.2020.102377.
Pascual-Goñi, E., Fortea, J., Martínez-Domeño, A., Rabella, N., Tecame, M., Gómez-Oliva, C., Querol, L., and Gómez-Ansón, B. (2020). COVID-19-associated ophthalmoparesis and hypothalamic involvement. Neurol. Neuroimmunol. Neuroinflammation 7, https://doi.org/10.1212/nxi.0000000000000823.
Ponti, G., Maccaferri, M., Ruini, C., Tomasi, A., and Ozben, T. (2020). Biomarkers associated with COVID-19 disease progression. Crit. Rev. Clin. Lab Sci. 57: 389–399, https://doi.org/10.1080/10408363.2020.1770685.
Qin, C., Zhou, L., Hu, Z., Zhang, S., Yang, S., Tao, Y., Xie, C., Ma, K., Shang, K., and Wang, W. (2020). Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin. Infect. Dis. 71: 762–768, https://doi.org/10.1093/cid/ciaa248.
Raony, Í., de Figueiredo, C.S., Pandolfo, P., Giestal-de-Araujo, E., Oliveira-Silva Bomfim, P., and Savino, W. (2020). Psycho-neuroendocrine-immune interactions in COVID-19: potential impacts on mental health. Front. Immunol. 11: 1170, https://doi.org/10.3389/fimmu.2020.01170.
Réus, G.Z., Fries, G.R., Stertz, L., Badawy, M., Passos, I., Barichello, T., Kapczinski, F., and Quevedo, J. (2015). The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders. Neuroscience 300: 141–154, https://doi.org/10.1016/j.neuroscience.2015.05.018.
Rhie, S.J., Jung, E.-Y., and Shim, I. (2020). The role of neuroinflammation on pathogenesis of affective disorders. J. Exerc. Rehabil. 16: 2, https://doi.org/10.12965/jer.2040016.008.
Rokni, M., Hamblin, M.R., and Rezaei, N. (2020). Cytokines and COVID-19: friends or foes? Hum. Vaccines Immunother. 16: 2363–2365, https://doi.org/10.1080/21645515.2020.1799669.
Romagnolo, A., Balestrino, R., Imbalzano, G., Ciccone, G., Riccardini, F., Artusi, C.A., Bozzali, M., Ferrero, B., Montalenti, E., and Montanaro, E. (2020). Neurological comorbidity and severity of COVID-19. J. Neurol. 268: 762–769, https://doi.org/10.1007/s00415-020-10123-y.
Sadeghmousavi, S., and Rezaei, N. (2020). COVID-19 and multiple sclerosis: predisposition and precautions in treatment. SN Compr. Clin. Med. 2: 1802–1807, https://doi.org/10.1007/s42399-020-00504-9.
Saghazadeh, A. and Rezaei, N. (2020). Immune-epidemiological parameters of the novel coronavirus - a perspective. Expet Rev. Clin. Immunol. 16: 465–470, https://doi.org/10.1080/1744666x.2020.1750954.
Saleki, K., Banazadeh, M., Saghazadeh, A., and Rezaei, N. (2020). The involvement of the central nervous system in patients with COVID-19. Rev. Neurosci. 31: 453–456, https://doi.org/10.1515/revneuro-2020-0026.
Salvetti, M., Landsman, D., Schwarz-Lam, P., Comi, G., Thompson, A.J., and Fox, R.J. (2015). Progressive MS: from pathophysiology to drug discovery. Mult. Scler. J. 21: 1376–1384, https://doi.org/10.1177/1352458515603802.
Saraiva, L.R., Ibarra-Soria, X., Khan, M., Omura, M., Scialdone, A., Mombaerts, P., Marioni, J.C., and Logan, D.W. (2015). Hierarchical deconstruction of mouse olfactory sensory neurons: from whole mucosa to single-cell RNA-seq. Sci. Rep. 5: 1–17, https://doi.org/10.1038/srep18178.
Serrano-Castro, P., Estivill-Torrús, G., Cabezudo-García, P., Reyes-Bueno, J., Petersen, N.C., Aguilar-Castillo, M., Suárez-Pérez, J., Jiménez-Hernández, M., Moya-Molina, M., and Oliver-Martos, B. (2020). Impact of SARS-CoV-2 infection on neurodegenerative and neuropsychiatric diseases: a delayed pandemic? Neurologia 35: 245–251.
Silverman, M.N., Pearce, B.D., Biron, C.A., and Miller, A.H. (2005). Immune modulation of the hypothalamic-pituitary-adrenal (HPA) axis during viral infection. Viral Immunol. 18: 41–78, https://doi.org/10.1089/vim.2005.18.41.
Sinha, P., Matthay, M.A., and Calfee, C.S. (2020). Is a cytokine storm” relevant to COVID-19? JAMA Intern. Med. 180: 1152–1154, https://doi.org/10.1001/jamainternmed.2020.3313.
Steardo, L., and Verkhratsky, A. (2020). Psychiatric face of COVID-19. Transl. Psychiatry 10, https://doi.org/10.1038/s41398-020-00949-5.
Steardo, L., Steardo, L.Jr., Zorec, R., and Verkhratsky, A. (2020). Neuroinfection may contribute to pathophysiology and clinical manifestations of COVID‐19. Acta Physiol. 229: e13473.
Steenblock, C., Todorov, V., Kanczkowski, W., Eisenhofer, G., Schedl, A., Wong, M.-L., Licinio, J., Bauer, M., Young, A.H., and Gainetdinov, R.R. (2020). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the neuroendocrine stress axis. Mol. Psychiatr. 25: 1611–1617, https://doi.org/10.1038/s41380-020-0758-9.
Sternberg, E.M. (2006). Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. Nat. Rev. Immunol. 6: 318–328, https://doi.org/10.1038/nri1810.
Stojanovic, A., Martorell, L., Montalvo, I., Ortega, L., Monseny, R., Vilella, E., and Labad, J. (2014). Increased serum interleukin-6 levels in early stages of psychosis: associations with at-risk mental states and the severity of psychotic symptoms. Psychoneuroendocrinology 41: 23–32, https://doi.org/10.1016/j.psyneuen.2013.12.005.
Strafella, C., Caputo, V., Termine, A., Barati, S., Caltagirone, C., Giardina, E., and Cascella, R. (2020). Investigation of genetic variations of IL6 and IL6R as potential prognostic and pharmacogenetics biomarkers: implications for COVID-19 and neuroinflammatory disorders. Life 10: 351, https://doi.org/10.3390/life10120351.
Ströhle, A. and Holsboer, F. (2003). Stress responsive neurohormones in depression and anxiety. Pharmacopsychiatry 36 (Suppl. 3): 207–214.
Tang, Y., Liu, J., Zhang, D., Xu, Z., Ji, J., and Wen, C. (2020). Cytokine storm in COVID-19: the current evidence and treatment strategies. Front. Immunol. 11: 1708, https://doi.org/10.3389/fimmu.2020.01708.
Terpos, E., Ntanasis‐Stathopoulos, I., Elalamy, I., Kastritis, E., Sergentanis, T.N., Politou, M., Psaltopoulou, T., Gerotziafas, G., and Dimopoulos, M.A. (2020). Hematological findings and complications of COVID‐19. Am. J. Hematol 95: 834–847.
Toljan, K. (2020). Letter to the editor regarding the “viewpoint evidence of the COVID-19 virus targeting the CNS: tissue distribution, host–virus interaction, and proposed neurotropic mechanism”. ACS Chem. Neurosci. 11: 1192–1194, https://doi.org/10.1021/acschemneuro.0c00174.
Ulhaq, Z.S., and Soraya, G.V. (2020). Interleukin-6 as a potential biomarker of COVID-19 progression. Med. Maladies Infect 50: 382–383.
Unal, G., Turan, B., and Balcioglu, Y.H. (2020). Immunopharmacological management of COVID-19: potential therapeutic role of valproic acid. Med. Hypotheses 143: 109891.
Valencia-Sanchez, C., and Wingerchuk, D.M. (2020). A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19. Mult. Scler. Relat. Disord. 42: 102182, https://doi.org/10.1016/j.msard.2020.102182.
Vaninov, N. (2020). In the eye of the COVID-19 cytokine storm. Nat. Rev. Immunol. 20: 277, https://doi.org/10.1038/s41577-020-0305-6.
Wagner, J., DuPont, A., Larson, S., Cash, B., and Farooq, A. (2020). Absolute lymphocyte count is a prognostic marker in Covid‐19: a retrospective cohort review. Int. J. Lab. Hematol. 42: 761–765, https://doi.org/10.1111/ijlh.13288.
Wang, L.A., de Kloet, A.D., Smeltzer, M.D., Cahill, K.M., Hiller, H., Bruce, E.B., Pioquinto, D.J., Ludin, J.A., Katovich, M.J., and Raizada, M.K. (2018). Coupling corticotropin-releasing-hormone and angiotensin converting enzyme 2 dampens stress responsiveness in male mice. Neuropharmacology 133: 85–93, https://doi.org/10.1016/j.neuropharm.2018.01.025.
Wang, H., Luo, S., Shen, Y., Li, M., Zhang, Z., Dong, Y., Zhou, H., Lin, L., Guo, W., and Kang, Z. (2020). Multiple enzyme release, inflammation storm and hypercoagulability are prominent indicators for disease progression in COVID-19: a multi-centered, correlation study with CT imaging score. Lancet Infect. Dis. preprint.
Wei, Y. and Shah, R. (2020). Substance use disorder in the COVID-19 pandemic: a systematic review of vulnerabilities and complications. Pharmaceuticals 13: 155, https://doi.org/10.3390/ph13070155.
Wheatland, R. (2004). Molecular mimicry of ACTH in SARS–implications for corticosteroid treatment and prophylaxis. Med. Hypotheses 63: 855–862, https://doi.org/10.1016/j.mehy.2004.04.009.
Wong, S.H., Lui, R.N., and Sung, J.J. (2020). Covid‐19 and the digestive system. J. Gastroenterol. Hepatol. 35: 744–748, https://doi.org/10.1111/jgh.15047.
Wu, J., Huang, J., Zhu, G., Wang, Q., Lv, Q., Huang, Y., Yu, Y., Si, X., Yi, H., and Wang, C. (2020). Elevation of blood glucose level predicts worse outcomes in hospitalized patients with COVID-19: a retrospective cohort study. BMJ Open Diabetes Res. Care 8: e001476, https://doi.org/10.1136/bmjdrc-2020-001476.
Xia, H. and Lazartigues, E. (2008). Angiotensin‐converting enzyme 2 in the brain: properties and future directions. J. Neurochem. 107: 1482–1494, https://doi.org/10.1111/j.1471-4159.2008.05723.x.
Xia, H. and Lazartigues, E. (2010). Angiotensin-converting enzyme 2: central regulator for cardiovascular function. Curr. Hypertens. Rep. 12: 170–175, https://doi.org/10.1007/s11906-010-0105-7.
Xu, H., Zhong, L., Deng, J., Peng, J., Dan, H., Zeng, X., Li, T., and Chen, Q. (2020). High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int. J. Oral Sci. 12: 1–5, https://doi.org/10.1038/s41368-020-0074-x.
Xu, P., Zhou, Q., and Xu, J. (2020). Mechanism of thrombocytopenia in COVID-19 patients. Ann. Hematol. 99: 1205–1208, https://doi.org/10.1007/s00277-020-04019-0.
Yan, Q., Li, P., Ye, X., Huang, X., Mo, X., Wang, Q., Zhang, Y., Luo, K., Chen, Z., and Luo, J. (2020). Longitudinal peripheral blood transcriptional analysis of COVID-19 patients captures disease progression and reveals potential biomarkers. MedRxiv preprint.
Zéphir, H. (2018). Progress in understanding the pathophysiology of multiple sclerosis. Rev. Neurol. 174: 358–363, https://doi.org/10.1016/j.neurol.2018.03.006.
Zhang, L., and Guo, H. (2020). Biomarkers of COVID-19 and technologies to combat SARS-CoV-2. Adv. Biomarkers Sci. Technol 1: 1–23.
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., and Huang, C.-L. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579: 270–273, https://doi.org/10.1038/s41586-020-2012-7.
Zhou, Y., Li, B., Liu, J., and Chen, D. (2020). The predictive effectiveness of blood biochemical indexes for the severity of COVID-19. Can. J. Infect Dis. Med. Microbiol. 2020, https://doi.org/10.1155/2020/7320813.
Zou, X., Chen, K., Zou, J., Han, P., Hao, J., and Han, Z. (2020). Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front. Med. 14: 185–192, https://doi.org/10.1007/s11684-020-0754-0.